Shang Hai Zheng Quan Bao·2025-09-01 21:11Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its generic drugs to pass the consistency evaluation of quality and efficacy, which is expected to enhance market competitiveness for the products [1][11]. Drug Information 1. Cefoperazone Sodium and Sulbactam Sodium Injection - The drug has been approved in three specifications: 1.0g, 1.5g, and 2.0g [1][6] - It is a third-generation cephalosporin antibiotic used for various infections, including respiratory, urinary, and intra-abdominal infections [6] - The product was originally developed by Pfizer and was first launched in Japan in June 1986, with its 1.0g specification approved in China in 1996 [6] - The sales revenue for Tianxin Pharmaceutical's cefoperazone sodium and sulbactam sodium injection in 2024 is projected to be RMB 15.897 million [7] - The company has invested approximately RMB 7.9186 million in the research and development of this product [7] 2. Clindamycin Phosphate Injection - The drug is available in two specifications: 2ml: 0.3g and 4ml: 0.6g, and was launched in 2006 [8][9] - It is primarily used for severe infections caused by sensitive anaerobic bacteria [9] - The sales revenue for Tianxin Pharmaceutical's clindamycin phosphate injection in 2024 is projected to be RMB 7.50787 million [10] - The company has invested approximately RMB 2.7329 million in the research and development of this product [10]